Target intelligence / Profile preview

DNA-dependent metalloprotease SPRTN (SPRTN) (SPRTN)

Target
SPRTN
Molecular classification
Enzyme, Protease, DNA-dependent metalloprotease
01

Overview

DNA-dependent metalloprotease SPRTN (SPRTN), also known as Spartan, is an essential enzyme responsible for the repair of DNA-protein crosslinks (DPCs), which are toxic lesions that impede DNA replication and transcription (UniProt Q9H040). SPRTN functions by proteolytically cleaving proteins that have become covalently trapped on DNA, such as Topoisomerase 1 or proteins crosslinked by endogenous aldehydes, thereby allowing the replication fork to progress (Vaz et al., 2016, Molecular Cell). This activity is tightly regulated and coupled to DNA replication to prevent unscheduled degradation of chromatin proteins (Moro et al., 2023, Nature Communications). Mutations in the SPRTN gene are the underlying cause of Ruijs-Aalfs syndrome (RJALS), a rare autosomal recessive disorder characterized by genomic instability, early-onset hepatocellular carcinoma, and progeroid features (Lessel et al., 2014, Nature Genetics). While no clinical drugs currently target SPRTN, it is an emerging target in oncology research; its inhibition is hypothesized to sensitize cancer cells to chemotherapeutic agents that induce DPCs (Reinking et al., 2020, Journal of Biological Chemistry). However, because SPRTN is vital for maintaining genome integrity, therapeutic strategies must carefully manage the risk of inducing systemic DNA damage and premature aging (Stingele et al., 2016, Molecular Cell).

Other names
SpartanDVC1C1orf124Sprat-like proteinDNA-binding protein SPRTN
02

Mechanism of action

Proteolytic degradation of DNA-protein crosslinks to facilitate DNA replication fork progression; theoretical inhibition to sensitize cancer cells to DNA-damaging agents.

03

Biological functions

DNA-protein crosslink repairDNA replicationGenome stabilityDNA damage response
04

Disease associations

Ruijs-Aalfs syndromeHepatocellular carcinomaProgeroid syndromeCancer
05

Safety considerations

Genomic instabilityPremature aging (progeria)Increased risk of hepatocellular carcinomaSystemic toxicity due to essential role in DNA replication
06

Biomarkers

SPRTN mutation statusDNA-protein crosslink (DPC) accumulationSPRTN protein expression levels

Beyond the preview

Go deeper on DNA-dependent metalloprotease SPRTN (SPRTN) (SPRTN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on DNA-dependent metalloprotease SPRTN (SPRTN) (SPRTN).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call